Navigation Links
Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
Date:9/24/2009

ATLANTA, Sept. 24 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), was pleased to hear the announcement today of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine owned by Sanofi-Aventis and Global Solutions for Infectious Diseases. The completed study represents the first HIV/AIDS vaccine trial to show prevention of infection.

Robert McNally, Ph.D., Chief Executive Officer and President stated, "The results are highly encouraging for the clinical studies of our HIV/AIDS vaccine and we congratulate the Thai ministry of Public Health for successful conduct of a groundbreaking trial that included 16,000 volunteers and was supported by multiple agencies including the U.S. Army and the U.S. National Institutes of Health (NIH)."

"The partial success of this trial is very important to the GeoVax vaccine, because the vaccine tested in Thailand, like the GeoVax vaccine, was designed to elicit both T cells and antibody," said Dr. Harriet Robinson, Senior Vice President of Research & Development. "The two vaccines that have failed in previous efficacy trials elicited only antibody or only T cells. This was the first efficacy test of a vaccine that elicited both antibody and T cells and is very encouraging for the GeoVax vaccine, because our vaccine generates higher frequencies of T cells and better quality antibody. Given what we know about the elicited responses observed in this study, and the similarities and differences between our vaccine and the Sanofi-Aventis vaccine, the GeoVax vaccine should be poised for a higher level of protective success than the 30% success rate achieved in Thailand," noted Dr. Robinson.

"Within the two main areas of focus for our HIV/AIDS v
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
2. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
3. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
4. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
5. Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia
6. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
11. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014  Next month, executives from clinical trial marketing ... events beginning with Patient-Centered Clinical Trials 2014 , to ... Boston , September 4-5. Patient recruitment experts Bonnie ... Fleishman will share insights on the benefits of employing ... tactics – from media to mobile apps – can be ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/28/2014)... 28, 2014 Supplementing their complete ... promotion for Eppendorf Safe Lock Centrifuge Tubes ... the highest quality tubes at an affordable price. ... customers doing chemical, medical, pharmaceutical, and life science ... not regularly able to afford Eppendorf products. , ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... Its that time again for the half-year roundup of stock market ... you recall the results from the first quarter, it was pretty ... percent , Nasdaq National Market down 8 percent , Nasdaq Biotech ... isnt a great trend. As you can see below, the results ...
... International, a supplier of automatic identification and data collection ... 4.0 of their NiceLabel software. , ,The new versions ... radio frequency identification (RFID) tags, as well as an ... with Windows programs such as Microsoft Access, Windows Event ...
... As NASA works to get the Space Shuttle Discovery ... be monitored by NASA flight surgeons using GE Healthcare's ... health information will enable NASA to monitor and track the ... the sharing also of information with experts located outside NASA's ...
Cached Biology Technology:Midwest large cap life sciences mostly outperform market 2Midwest large cap life sciences mostly outperform market 3
(Date:8/28/2014)... for your neighbors than traditional cigarettes, but still ... new study from USC. , Scientists studying secondhand ... in exposure to harmful particles, with close-to-zero exposure ... some harmful metals in second-hand e-cigarette smoke were ... smoke contains high levels of polycyclic aromatic hydrocarbons ...
(Date:8/28/2014)... (August 28, 2014) Researchers at the University of ... muscular dystrophy (FSHD) to be used for muscle regeneration ... potential therapies for FSHD. , The research is published ... Reports . , There is no treatment for FSHD, ... common type of muscular dystrophy. FSHD is an unusual ...
(Date:8/28/2014)... on-off switch for Streptomyces , a group of ... world,s naturally derived antibiotic medicines. , Their hope ... to manipulate this switch to make nature,s antibiotic factory ... in Cell , found that a unique interaction ... protein called BldD ultimately controls whether a bacterium spends ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... the wind, but a new study in the October 14th ... confirms that they are anything but drifters. A previous ... evidence that Silver Y moths rely on a sophisticated internal ... destination within a matter of days. Now, the research team ...
... mouse heart has an astounding capacity to regenerate, ... The research, published by Cell Press in the ... Cell , describes the previously unrecognized potential of ... compensatory proliferation of healthy cells. Disorders of ...
... why people who eat more fruit and vegetables may gain ... that a fragment released from pectin, found in all fruits ... 3 (Gal3), a protein that plays a role in all ... effects of foods are based on population studies," says Professor ...
Cached Biology News:Migratory moths may hitch their rides, but they're anything but drifters 2Embryonic heart exhibits impressive regenerative capacity 2Pectin power 2
...
Red Standard is sodium salt of resorufin....
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
Oligodendrocyte Marker O1 MAb (Clone O1)...
Biology Products: